Presentation Information
[O2-03]Safety of risdiplam in Japanese Patients with spinal muscular atrophy: Interim Analysis of Post-Marketing Surveillance
○Kayoko Saito1, Toshio Saito2, Reiko Arakawa3, Yasuhiro Takeshima4, Hisahide Nishio5, Yuka Ishikawa6, Masahisa Katsuno7, Takahiko Tsumuraya8, Hiromitsu Kawata9, Yuki Miyano8, Hirofumi Komaki10 (1.Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan, 2.Division of Child Neurology, Department of Neurology, Osaka Toneyama Medical Center, Osaka, Japan, 3.Department of Genomic Medicine, National Center for Global Health and Medicine, Tokyo, Japan, 4.Department of Pediatrics, Hyogo Medical University Hospital, Hyogo, Japan, 5.Faculty of Rehabilitation, Kobe Gakuin University, Hyogo, Japan, 6.Center for Neuromuscular Disease, Child Health and Development, National Hospital Organization, Hokkaido Medical Center, Sapporo, Hokkaido, Japan, 7.Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 8.Drug Safety Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 9.Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 10.Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan)